[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346721-105":59,"doc-detail-346721-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","nanomedicine-targeting-cancer-associated-fibroblasts-in-prostate-cancer-from-biological-mechanisms-to-integrated-theranostic-strategies","Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies","","Prostate cancer (PCa) is the second most common malignancy in men worldwide, with advanced disease driven by heterogeneity, metastasis, and resistance to androgen deprivation therapy and chemotherapy. Cancer-associated fibroblasts (CAFs) dominate the tumor microenvironment and shape tumor progression, metastatic spread, and treatment resistance. Nanomedicine enables engineered nanoparticles for precise CAF drug delivery, enhanced bioavailability, and multimodal theranostics that couple diagnosis with therapy. The review surveys CAF biology, nanomaterial targeting approaches, theranostic nanoplatforms, and key challenges including CAF heterogeneity and biosafety, concluding with future directions such as gene-editing integration and immunotherapy synergy.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nanomedicine-targeting-cancer-associated-fibroblasts-in-prostate-cancer-from-biological-mechanisms-to-integrated-theranostic-strategies/346721/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nanomedicine-targeting-cancer-associated-fibroblasts-in-prostate-cancer-from-biological-mechanisms-to-integrated-theranostic-strategies/346721.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-17","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",14,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are cancer-associated fibroblasts (CAFs) important in prostate cancer progression?","Question",{"text":113,"@type":114},"CAFs are the predominant stromal cells in the prostate cancer tumor microenvironment and critically drive tumor progression, metastasis, and therapeutic resistance.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does nanomedicine help target CAFs in prostate cancer?",{"text":118,"@type":114},"Nanomedicine uses engineered nanomaterials to achieve precise drug delivery to CAFs, improve bioavailability, and support multimodal theranostic functions that integrate diagnosis with therapy.",{"name":120,"@type":111,"acceptedAnswer":121},"What key challenges and future directions does the review highlight?",{"text":122,"@type":114},"Key challenges include CAF heterogeneity and nanomaterial biosafety. Future directions include integrating gene-editing approaches, developing multi-stimuli-responsive systems, and combining with synergistic immunotherapy.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},346721,1790450774,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW  \nNanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies  \nFajiang Qian 1 , *, Jingfeng Zhou 2 , *, Yuan Tang 3 , *, Junhao Chen 4 , *, Jieming Zuo4 , *, Keyi Gou2 , Chenxi Tan2 , Jingcheng Fang2 , Zihan Zhao 2 , Junxian Zhao 5 , Lingxiang Wen 6 , Shi Fu4 , Jintao Yang 1 , Chengjie Wang 7 , Zhongsong Zhang 2  \n1Department of Urology, Lincang People’s Hospital, Lincang, Yunnan, 677000, People’s Republic of China; 2School of Clinical Medicine, Chengdu Medical College, Chengdu, Sichuan, 610550, People’s Republic of China; 3School of Nursing, Chengdu Medical College, Chengdu, Sichuan, 610550, People’s Republic of China; 4Department of Urology, The Second Affiliated of Kunming Medical University, Kunming, Yunnan, 650032, People’s Republic of China; 5Department of Urology, 920th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Kunming, Yunnan, 650032, People’s Republic of China; 6School of Clinical Medicine, Kunming Medical University, Kunming, Yunnan, 650032, People’s Republic of China; 7School of Stomatology, Xinjiang Second Medical College, Karamay, Xinjiang, 834000, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Jingfeng Zhou; Zhongsong Zhang, Email [2833827616@qq.com](2833827616@qq.com); [zzscmc1122@163.com](zzscmc1122@163.com)  \n\n| Abstract: Prostate cancer (PCa) is the second most common malignancy in men worldwide. Advanced stages are characterized by tumor heterogeneity, metastasis, and resistance to androgen deprivation therapy and chemotherapy. Cancer-associated fibroblasts (CAFs), the predominant stromal cells in the PCa tumor microenvironment (TME), critically drive tumor progression, metastasis, and therapeutic resistance. Nanomedicine represents a transformative strategy for targeting CAFs. It leverages engineered nanomaterials to achieve precise drug delivery, improved bioavailability, and multimodal theranostic capabilities, which integrate diagnosis with therapy. This review comprehensively examines advances in nanomaterial-based strategies for CAF-targeted therapy in PCa. We first delineate the biology of CAFs in PCa, encompassing their origins, activation mechanisms, key markers (e.g, α-SMA and FAP), phenotypic heterogeneity, and intricate crosstalk with cancer cells, immune cells, and the extracellular matrix (ECM) . We then evaluate nanomaterial-based targeting strategies and therapeutic modalities, including CAF depletion, reprogramming, and extracellular matrix remodeling, for the treatment of PCa. Subsequently, we discuss CAF-targeted nanoplatforms for theranostics, including molecular imaging probes (e.g., 68Ga-FAPI) and image-guided delivery systems that integrate precise diagnosis with therapy. Finally, we address key challenges, particularly CAF heterogeneity and nanomaterial biosafety, and outline future directions, including gene-editing integration, multi-stimuli-responsive systems, and synergistic immunotherapy combinations. Collectively, this review underscores the transformative potential of integrating CAF biology with nanotechnology to overcome therapeutic resistance in PCa and advance precision oncology.\u003Cbr>Keywords: cancer-associated fibroblasts, prostate cancer, tumor microenvironment, nanomedicine, diagnostics and therapeutics, targeted therapy |\n| --- |\n| Introduction\u003Cbr>Prostate cancer (PCa) is the second most common malignancy in men worldwide, accounting for approximately 7.8% of all cancer cases.1 It is particularly prevalent in individuals over 65 and exhibits higher incidence rates in regions such as Africa and Northern Europe.2 Standard treatments, including surgery, androgen deprivation therapy (ADT), radiotherapy, and chemotherapy, have substantially improved the prognosis of localized disease. However, the management of advanced and metastatic PCa r","cbCaig4YJoAqBy9u","https://ap.wps.com/l/cbCaig4YJoAqBy9u","pdf",10812317,32,"English","# Abstract\n# Introduction\n## Prostate cancer burden and treatment challenges\n## Tumor microenvironment and resistance mechanisms\n# Review Overview\n## CAF biology in prostate cancer\n## Nanomedicine targeting strategies for CAFs\n## CAF-targeted theranostic nanoplatforms\n## Challenges and future directions","[{\"question\":\"Why are cancer-associated fibroblasts (CAFs) important in prostate cancer progression?\",\"answer\":\"CAFs are the predominant stromal cells in the prostate cancer tumor microenvironment and critically drive tumor progression, metastasis, and therapeutic resistance.\"},{\"question\":\"How does nanomedicine help target CAFs in prostate cancer?\",\"answer\":\"Nanomedicine uses engineered nanomaterials to achieve precise drug delivery to CAFs, improve bioavailability, and support multimodal theranostic functions that integrate diagnosis with therapy.\"},{\"question\":\"What key challenges and future directions does the review highlight?\",\"answer\":\"Key challenges include CAF heterogeneity and nanomaterial biosafety. Future directions include integrating gene-editing approaches, developing multi-stimuli-responsive systems, and combining with synergistic immunotherapy.\"}]","Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies | PDF",1790062523,81,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/256a2170500003db17761e0f4b96efbe.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b2af9b9b4112b0f89bc0a4f63235c8c.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6921df390f0a4fc5effb44ee820d17b5.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57b9b42589e7f31237a92951c679ffab.webp",980,1268]